SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Halladay Benjamin
(Last) (First) (Middle)
C/O ESPERION THERAPEUTICS, INC.
3891 RANCHERO DRIVE, SUITE 150
(Street)
ANN ARBOR MI 48108
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/16/2022 		3. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 19,771(1)(2)(3)(4)(5) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes an award of restricted stock units ("RSUs"), of which 152 RSUs are currently unvested. Such award vests over a four (4) year period as follows: 25% vested on January 20, 2021 and the remainder vests in equal quarterly installments over the three (3) year period thereafter, subject to continued service.
2. Includes an award of RSUs, of which 312 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on May 15, 2021, subject to continued service.
3. Includes an award of RSUs, of which 309 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on October 15, 2021, subject to continued service.
4. Includes an award of RSUs, of which 5,470 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on June 15, 2022, subject to continued service.
5. Includes an award of RSUs, of which 7,800 RSUs are currently unvested. Such award will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label, subject to continued service.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Benjamin Looker, by power of attorney 11/16/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.